司库奇尤单抗治疗银屑病伴代谢综合征患者的临床疗效

Clinical Efficacy of Skuchizumab in Treatment of Psoriasis with Metabolic Syndrome

目的观察司库奇尤单抗治疗银屑病伴代谢综合征的疗效。方法纳入2022年6月至2023年10月期间在我院就诊治疗的斑块型银屑病伴代谢综合征患者。将所有患者随机分为观察组和对照组,每组各40例。观察组给予司库奇尤单抗皮下注射,对照组给予氨甲蝶呤口服治疗,均持续治疗52周。观察两组的临床总有效率、治疗前后PASI评分(评估疾病严重程度,分值越高,病情越重)变化及不良反应率。结果治疗52周后,观察组总有效率97.5%,高于对照组的62.5%(P<0.05);对照组对血脂血压血糖代谢无影响,观察组对血压血糖无影响,但可调节血脂代谢;观察组PASI评分低于对照组(P<0.05);观察组未出现不良反应,对照组共出现7例(17.5%)不良反应(P<0.05)。结论在对重度斑块型银屑病伴代谢综合征患者,采用司库奇尤单抗注射液相比传统氨甲蝶呤治疗效果更优,改善疾病严重程度的同时,还可调节血脂代谢,且不良反应低。

Objective To observe the clinical efficacy of skuchizumab in treatment of psoriasis with metabolic syndrome.Methods Patients with plaque psoriasis with metabolic syndrome who visited our hospital for treatment between June 2022 and October 2023 were included.All patients were randomly divided into observation group and control group,40 cases in each group.The observation group was given subcutaneous injection of sterculizumab,and the control group was given oral treatment of methotrexate,both of which continued to be treated for 52 weeks.The total clinical effectiveness rate,PASI score(to assess the severity of the disease,the higher the score,the more serious the disease)and the rate of adverse reactions were observed in the two groups before and after treatment.Results After 52 weeks of treatment,the total effective rate of the observation group was 97.5%,which was higher than that of the control group,which was 62.5%(P<0.05);the control group had no effect on the metabolism of blood lipids,blood pressure,and blood glucose,and the observation group had no effect on blood pressure and blood glucose,but it could regulate the metabolism of blood lipids;the PASI score of the observation group was lower than that of the control group(P<0.05);the observation group did not show any adverse reactions,and the control group showed a total of 7 cases(17.5%)of adverse reactions(P<0.05).Conclusions In patients with severe plaque-type psoriasis with metabolic syndrome,the use of stauchyuzumab injection is more effective compared with traditional methotrexate,improving the severity of the disease while regulating lipid metabolism,and has low adverse reactions.